AST Longevity-Medicine Target Ranges for Women: What Your Number Really Means

What AST Actually Measures

AST is an enzyme found in your liver cells, heart muscle, skeletal muscle, kidneys, and red blood cells. When any of those tissues are under stress or actively damaged, AST leaks into your bloodstream. Your result is a sum signal from multiple organs, which is exactly why the AST/ALT ratio matters more than AST alone.

Your liver holds the highest concentration of both AST and its partner enzyme ALT (alanine aminotransferase). ALT is more liver-specific, while AST reflects a broader tissue picture. A 2022 analysis in Hepatology confirmed that combined AST/ALT patterns classify liver injury subtype with far greater accuracy than either marker alone, a finding that directly shapes how longevity clinicians read your panel.

Why "Normal" Is Not the Same as "Optimal"

Standard reference ranges are built from population averages, not from the healthiest individuals in a population. Labs in the United States typically flag AST above 35-40 U/L in women as abnormal, but those thresholds were set on mixed-sex cohorts that included people with subclinical metabolic liver disease, obesity, and sedentary lifestyles.

A landmark reanalysis published in Annals of Internal Medicine found that recalculating reference intervals using only metabolically healthy blood donors dropped the upper normal limit for ALT to 19 U/L in women and 30 U/L in men, a pattern that longevity practitioners now apply to AST as well. The takeaway: a result labeled "normal" by your lab printout may still sit well above the range associated with long-term liver and cardiovascular health.

AST as a Longevity Biomarker

Population cohort data associate chronically elevated AST with all-cause mortality risk even within the so-called normal range. The UK Biobank analysis (N = 361,776) published in PLOS Medicine showed that AST above 25 U/L was independently associated with hepatic fibrosis risk regardless of BMI, a relationship that held in women across all age groups studied. Longevity clinicians use this data to justify a tighter target of <20 U/L for women.

The AST/ALT Ratio: The Number Your Doctor May Not Mention

The ratio of AST to ALT tells you more about the origin of enzyme elevation than either value in isolation.

An AST/ALT ratio below 1.0 indicates a liver-dominant pattern consistent with nonalcoholic fatty liver disease (NAFLD) or viral hepatitis in early stages. A ratio above 2.0 strongly suggests alcohol-related liver disease, and a ratio above 1.0 with normal total values can point to muscle origin (exercise, hypothyroidism, or myositis) rather than liver pathology at all. A 2018 meta-analysis in Alimentary Pharmacology and Therapeutics found an AST/ALT ratio >1 had a positive likelihood ratio of 4.5 for alcohol-related liver disease when AST exceeded 50 U/L.

For longevity purposes, your optimal profile is:

• AST <20 U/L
• ALT <19 U/L (women-specific recalculated threshold)
• AST/ALT ratio <1.0

If your AST is higher than your ALT and both are modestly elevated (say, AST 28, ALT 22), muscle-source elevation becomes the leading explanation before liver disease.

When Muscle Drives Your AST Up

A hard leg day at the gym can push AST to 60-80 U/L within 24-48 hours in women with significant muscle mass. Research in the Journal of Athletic Training documented mean AST values of 72 U/L in female collegiate athletes after intense eccentric exercise, values that normalize within five to seven days of rest. This is why longevity panels should be drawn fasted and at least 48 hours after strenuous exercise.

Hypothyroidism is another common female-specific driver. A study in Thyroid (2014) found that untreated hypothyroidism raised AST in women by a mean of 11 U/L through impaired muscle enzyme clearance, and that values normalized within six weeks of thyroid replacement. If your TSH is elevated alongside your AST, treat the thyroid first before investigating the liver.

How Hormones and Life Stage Change Your AST

Sex hormones directly regulate hepatic enzyme activity. This is one of the most under-recognized sources of sex-based variation in liver panels, and clinical trial data in women specifically are limited. The majority of reference-range studies were conducted in mixed-sex or predominantly male cohorts, so extrapolation to women is explicit here.

Reproductive Years

Estrogen promotes hepatic lipid processing and reduces baseline liver inflammation. During your reproductive years, estrogen's anti-inflammatory signaling likely keeps AST lower than it would be otherwise. A cross-sectional study in Gut (2021) found women aged 20-45 had mean AST 3-5 U/L lower than age-matched men, a difference that disappeared after menopause.

Menstrual cycle phase has a modest but measurable effect. AST may rise by 2-4 U/L in the luteal phase relative to the follicular phase, likely from progesterone-related changes in hepatic enzyme kinetics. This variation is small enough that it rarely changes clinical interpretation, but it is a reason not to rely on a single data point if your value sits near a threshold.

Trying to Conceive and Fertility Treatment

If you are undergoing ovarian stimulation for IVF, high-dose gonadotropins and the estrogen surge of controlled ovarian hyperstimulation can transiently raise AST by 10-20 U/L. ASRM practice guidelines note that mild transaminase elevation during stimulation does not require dose adjustment unless values exceed three times the upper limit of normal, a threshold of roughly 105-120 U/L by standard lab reference.

Perimenopause

The perimenopausal transition is associated with rising AST in many women, beginning roughly two to three years before the final menstrual period. Fluctuating estrogen alters hepatic lipid metabolism, and the concurrent rise in visceral adiposity increases fatty acid flux to the liver. Data from the Study of Women's Health Across the Nation (SWAN) showed a statistically significant increase in liver enzymes during the menopausal transition that was partially attenuated by hormone therapy use. If you are in perimenopause and your AST is trending up on serial testing, metabolic liver disease screening (liver ultrasound, FIB-4 index) is appropriate.

Postmenopause

After your final menstrual period, estrogen loss removes a degree of hepatoprotective signaling. Population data show postmenopausal women have AST values approximately 10-15% higher than premenopausal counterparts at the same body weight and metabolic profile. The 2019 European Association for the Study of the Liver (EASL) clinical practice guidelines recommend using sex-specific and age-adjusted reference ranges for liver enzymes, a recommendation that many U.S. Labs have still not implemented.

Menopausal hormone therapy (MHT) may lower AST modestly. Oral estrogen increases sex hormone-binding globulin and alters hepatic first-pass metabolism, and some cohort data show 3-7 U/L reductions in AST with estrogen-only MHT. Transdermal estrogen has a smaller hepatic effect because it bypasses first-pass liver metabolism. If you are on MHT and your AST is rising, the MHT is unlikely to be the cause, but your clinician may consider switching from oral to transdermal to reduce hepatic load.

AST and Female-Specific Conditions

Several conditions that disproportionately affect women alter AST independently of alcohol or primary liver disease.

PCOS

Polycystic ovary syndrome is the most common endocrine disorder in reproductive-age women, affecting an estimated 8-13% of women globally according to the WHO. Insulin resistance, the central metabolic feature of PCOS, drives hepatic fat accumulation, and a meta-analysis in Human Reproduction Update (2015) found that women with PCOS had a significantly higher prevalence of elevated liver enzymes (odds ratio 2.5 for elevated ALT; AST trended similarly). If you have PCOS and an AST above 20 U/L, NAFLD is a meaningful concern that warrants a liver ultrasound and fasting insulin assessment.

Hypothyroidism and Hashimoto's Thyroiditis

As noted above, hypothyroidism raises AST through muscle-clearance impairment. Hashimoto's thyroiditis, the autoimmune thyroid condition that accounts for the majority of hypothyroidism in women, is ten times more common in women than men. If your TSH is above 4.5 mIU/L alongside an elevated AST, optimizing thyroid replacement is the first step, not a liver biopsy.

Celiac Disease

Celiac disease affects women twice as often as men. A 2015 study in Alimentary Pharmacology and Therapeutics found that 40% of women with newly diagnosed celiac disease had elevated transaminases (AST or ALT) that fully resolved on a gluten-free diet within 12 months. Celiac should be on the differential any time liver enzyme elevation is unexplained in a woman, particularly if she has autoimmune thyroid disease or iron-deficiency anemia.

Autoimmune Hepatitis

Autoimmune hepatitis (AIH) is three to four times more common in women than men. It can present with AST values ranging from mildly elevated (30-50 U/L) to dramatic (above 500 U/L) during flares. The American Association for the Study of Liver Diseases (AASLD) AIH guidelines recommend ANA, ASMA, and IgG testing when unexplained AST elevation persists beyond three months in a woman, particularly if she carries other autoimmune diagnoses.

Pregnancy and Lactation: What Changes, What Warrants Concern

Liver physiology shifts substantially across pregnancy, and AST interpretation requires trimester-specific thinking.

First and Second Trimester

AST is generally stable or slightly lower in the first half of pregnancy relative to pre-pregnancy baseline. A 2010 reference-interval study in Clinical Chemistry and Laboratory Medicine established trimester-specific normal ranges and found the upper limit of normal for AST in the first trimester was 31 U/L and in the second trimester was 30 U/L, both modestly lower than non-pregnant reference ranges.

Third Trimester

AST rises modestly in normal late pregnancy due to increased placental production. Third-trimester upper normal is approximately 32-38 U/L by trimester-specific reference. Any AST above 70 U/L in the third trimester warrants same-day evaluation to exclude:

• HELLP syndrome (hemolysis, elevated liver enzymes, low platelets): AST may reach 200-4,000 U/L
• Acute fatty liver of pregnancy (AFLP): AST typically 300-500 U/L
• Intrahepatic cholestasis of pregnancy (ICP): AST often mildly elevated alongside bile acids

These are obstetric emergencies. If you are pregnant and receive a lab result with AST above 70 U/L, contact your obstetric provider the same day.

Lactation

AST is not a concern from a breastfeeding standpoint. It is an enzyme, not a drug, and does not transfer into breast milk in clinically meaningful amounts. Routine monitoring of AST during lactation is guided by whatever underlying condition prompted testing in the first place.

Contraception Note

This article does not cover a teratogenic drug, so a formal contraception requirement does not apply. If your elevated AST leads to a medication prescription (for example, metformin for PCOS-related NAFLD, or ursodeoxycholic acid for ICP), those medications carry their own pregnancy and contraception considerations that your prescriber will review.

Who Should Prioritize Optimizing AST

Not every woman needs to act on an AST of 22 U/L. Below is a practical framework for thinking about whether your number warrants intervention.

Women for Whom Optimization Matters Most

• Women with PCOS, metabolic syndrome, or type 2 diabetes: insulin resistance accelerates hepatic steatosis, and keeping AST below 20 U/L is a reasonable surrogate for liver health
• Perimenopausal and postmenopausal women: estrogen loss increases susceptibility to NAFLD progression
• Women on long-term medications metabolized hepatically: oral contraceptives (high-dose), tamoxifen, valproate, and methotrexate all have hepatic effects
• Women with a family history of cirrhosis or liver cancer

Women Who May Have Falsely Elevated AST

• Women who strength-train or compete in endurance sports: test at least 48 hours after last intense session
• Women with hypothyroidism not yet at goal TSH: normalize thyroid first, then recheck AST
• Women with untreated celiac disease: gluten-free diet often resolves the elevation without additional intervention

Women with Reassuringly Low AST

An AST below 15 U/L in the context of a normal ALT and normal GGT is a meaningful longevity signal. Low AST combined with low ALT and low GGT suggests minimal hepatic fat and low oxidative stress burden, a pattern associated in the PREVEND cohort study with lower all-cause mortality over a 10-year follow period.

How to Move Your AST Toward the Longevity Target

Lifestyle changes that reduce hepatic fat and inflammation reliably lower AST in women. The data are strongest for the following:

Weight and Metabolic Changes

A 5-7% reduction in body weight reduces liver fat content by roughly 30% and lowers AST by a mean of 10-17 U/L in women with NAFLD, based on a 2019 randomized trial in Gastroenterology. This magnitude of AST reduction from weight loss alone rivals some pharmaceutical interventions.

Dietary Pattern

A Mediterranean-style dietary pattern reduced AST by a mean of 8 U/L over 12 weeks in a Spanish randomized trial of women with elevated liver enzymes, even without significant weight change. Reducing fructose intake, particularly from sugar-sweetened beverages, targets de novo hepatic lipogenesis directly.

Exercise Timing for Accurate Testing

Exercise timing does not lower your true AST. It only prevents you from misreading a muscle-source elevation as a liver problem. Train hard, but schedule your longevity labs on a rest day or at least two days after your last intense session.

Coffee

Regular coffee consumption, three or more cups per day, is consistently associated with lower AST and reduced liver fibrosis risk across multiple cohort studies. A meta-analysis of 16 studies in Hepatology found each two-cup increment per day associated with a 44% lower risk of liver cirrhosis. The mechanism involves cafestol and kahweol, diterpenes with hepatoprotective signaling.

GLP-1 Receptor Agonists

GLP-1 receptor agonists (semaglutide, tirzepatide) are now under active investigation for NASH/MASLD. The ESSENCE trial (semaglutide 2.4 mg weekly in NASH) demonstrated significant AST reduction alongside histological improvement in liver fibrosis. Women with PCOS-related or obesity-related elevated AST who are already candidates for GLP-1 therapy for weight management may see AST improvement as a secondary benefit.

Reading Your Lab Report: A Practical Checklist

Before you conclude your AST is abnormal, verify these five points:

1. Was blood drawn fasted (at least 8 hours)? Non-fasted samples can show artifactual AST elevation.
2. Did you exercise intensely in the 48 hours before the draw? Muscle AST can double or triple post-workout.
3. Is your TSH in range? Hypothyroidism is the most common missed driver in women.
4. Are your ALT and GGT also elevated? If AST is elevated in isolation, muscle origin is more likely than liver origin.
5. What is your AST/ALT ratio? A ratio above 1.0 with both values below 50 U/L in a woman who drinks minimally points toward muscle, not alcohol or cirrhosis.

If AST is persistently above 25 U/L on two separate fasted, post-rest draws, the next step is a liver ultrasound and a full metabolic panel including fasting insulin, HbA1c, and a lipid panel. The FIB-4 index (calculated from age, AST, ALT, and platelet count) provides a non-invasive estimate of liver fibrosis risk and is recommended by the AASLD for NAFLD staging.